The mission of Oxygen Biotherapeutics is to research, develop and market oxygen related topical and intravenous products based on our perfluorocarbon technology.
Currently, we have one product candidate, Oxycyte PFC emulsion, in Phase IIb clinical trials in Switzerland and Israel for use in treating traumatic brain injury (TBI).
Products & Indications
Traumatic Brain Injury
Oxygen Biotherapeutics Receives Favorable NASDAQ Listing Decision
MORRISVILLE, N.C.--(BUSINESS WIRE)--May. 16, 2013-- Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), today announced that the NASDAQ Listing Qualifications Panel (the “Panel”) has granted the Company’s request for continued listing on The NASDAQ Capital Market pursuant to an extension through June 3, 2013 to evidence compliance with the minimum $1.00 bid price requirement and through July 31, 2013 to evidence compliance with the minimum $2.5 million stockholders’ equity requirement for continued listing on The NASDAQ Capital Market. more..
About Oxygen Biotherapeutics
Oxygen Biotherapeutics is the tissue oxygenation company
Oxygen is essential to life. When that supply is shut off the results can range from minor to devastating. At Oxygen Biotherapeutics, our goal is to help the human body maintain a sufficient oxygen supply to stop disease and damage to tissues that occurs when the flow of oxygen is suddenly interrupted or diminished.
Currently, we are developing medical and cosmetic products designed to deliver oxygen to specific tissues in the body that are deprived of oxygen. Our most advanced product, Oxycyte PFC, is in Phase IIb clinical trials in Switzerland and Israel for the traumatic brain injury. Oxycyte PFC is an intravenously delivered perfluorocarbon-based drug that we believe has therapeutic benefits for acute ischemic conditions. The first cohort of the Phase IIb trail is complete and efforts are being made to resume the trials later this fiscal year with planned expansions in other countries. more..